Market Capitalization

The insurance industry is all-in on AI, but a recent NYC conference revealed a critical flaw: the technology is only as good as the messy data it runs on.

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

As TopBuild shareholders face a critical merger deadline, QXO is assembling an industry titan. This move isn't just about size; it's a bid to reshape the future.

SpaceX's record-shattering $75 billion IPO promises unprecedented access for retail investors, but a sky-high valuation and governance red flags loom large.

BOXABL inks its first major multi-unit deal, signaling a new era for modular housing in Texas. But can it scale fast enough amidst a high-stakes SPAC merger?

A new alliance between Made Scientific and Pluristyx promises to slash the time and cost of developing advanced iPSC therapies. But can it deliver on its promise?

Facing dire financial warnings, Cosmos Health plans to sell its own facilities to fund a comeback. Is it a stroke of genius or a desperate final gambit?

A new integration between Amplify's AI-native platform and Wealthbox CRM tackles operational drag, signaling a strategic shift toward a more connected future for RIAs.

With historic funds flowing and AI's demands soaring, the Broadband Nation Expo is a critical juncture. Can industry leaders overcome the hurdles to connect America?

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.

Singapore's SuperX AI has opened a specialized cloud hub in Denver, revealing the high-stakes, global race to build the essential plumbing for our AI future.

NTT DATA's top ranking in agentic AI reveals a market pivot from pilot projects to production-ready systems, solving the 'pilot paralysis' plaguing enterprises.

As AI sweeps through medicine, Gigi Yuen-Reed's recognition highlights a crucial strategy: building systems that empower, not replace, human expertise.

At Money20/20, one firm showed how legal precedent and a patent moat are turning digital trust from a compliance headache into a core business asset.

NASDAQ's Eightco is selling a dream: single-stock access to AI's giants and the future of identity. But is it a visionary bet or a high-risk house of cards?

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.

A record $98.3T in HNWI wealth creates a fierce battle for assets, as traditional firms lose ground to tech-savvy rivals and AI-driven personalization.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

As security leaders prepare for the Gartner Summit, a new analyst watch list offers a roadmap to the AI-driven vendors and trends shaping the industry's bottom line.